Neoadjuvant/Phase 1 Study of CD40 Agonist (LVGN7409) and PD-1 Inhibitor (LVGN3616) in Patients With Resectable HPV-negative Head/Neck Squamous Cell Carcinoma (HNSCC)
Latest Information Update: 21 Feb 2025
At a glance
- Drugs Dalnicastobart (Primary) ; Pradusinstobart (Primary)
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 19 Jul 2024 Status changed from not yet recruiting to recruiting.
- 04 Jun 2024 Planned initiation date changed from 1 May 2024 to 1 Jul 2024.
- 19 Mar 2024 Planned initiation date changed from 1 Mar 2024 to 1 May 2024.